Paolo Tarantino: Few treatments in oncology allow to achieve more than 50% intracranial response rates, with durable efficacy

Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared ESMO Open’s post on X/Twitter, adding:

“One of the most critical features of novel ADCs is their emerging intracranial activity. Few treatments in oncology allow to achieve >50% intracranial response rates, with durable (PFS 15 months!!) efficacy. Interesting meta-analysis – follow ESMO for more!”

Quoting ESMOs post:

“In a meta-analysis of 10 studies by Michelin et al, published on ESMO Open, T-DXd was found associated with relevant intracranial activity among patients with breast cancer brain metastases (IC-ORR 61%, mPFS 15 months). Read the article here.”

Source: Paolo Tarantino/X and ESMO Open/X